DE10346913A1 - Acylhydrazonderivate - Google Patents

Acylhydrazonderivate Download PDF

Info

Publication number
DE10346913A1
DE10346913A1 DE10346913A DE10346913A DE10346913A1 DE 10346913 A1 DE10346913 A1 DE 10346913A1 DE 10346913 A DE10346913 A DE 10346913A DE 10346913 A DE10346913 A DE 10346913A DE 10346913 A1 DE10346913 A1 DE 10346913A1
Authority
DE
Germany
Prior art keywords
sgk
diseases
acylhydrazone
dyslipidemia
fibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10346913A
Other languages
English (en)
Inventor
Rolf Gericke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Priority to DE10346913A priority Critical patent/DE10346913A1/de
Priority to BRPI0415119-4A priority patent/BRPI0415119A/pt
Priority to JP2006529992A priority patent/JP2007509037A/ja
Priority to CNA2004800295750A priority patent/CN1863764A/zh
Priority to EP04765298A priority patent/EP1670751A1/de
Priority to PCT/EP2004/010398 priority patent/WO2005037773A1/de
Priority to US10/574,781 priority patent/US7405239B2/en
Priority to MXPA06003789A priority patent/MXPA06003789A/es
Priority to KR1020067006033A priority patent/KR20070029106A/ko
Priority to CA002542106A priority patent/CA2542106A1/en
Priority to RU2006115795/04A priority patent/RU2006115795A/ru
Priority to AU2004281906A priority patent/AU2004281906A1/en
Priority to ARP040103650A priority patent/AR046061A1/es
Publication of DE10346913A1 publication Critical patent/DE10346913A1/de
Priority to ZA200603631A priority patent/ZA200603631B/en
Priority to US12/100,987 priority patent/US20080214674A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones

Abstract

Neue Acylhydrazonderivate nach Anspruch 1 sind SGK-Inhibitoren und können zur Behandlung von SGK-bedingten Krankheiten und Leiden wie Diabetes, Fettsucht, metabolisches Sydrom (Dyslipidämie), systemische und pulmonale Hypertonie, Herzkreislauferkrankungen und Nierenerkrankungen, allgemein bei jeglicher Art von Fibrosen und entzündlichen Prozessen verwendet werden.
DE10346913A 2003-10-09 2003-10-09 Acylhydrazonderivate Withdrawn DE10346913A1 (de)

Priority Applications (15)

Application Number Priority Date Filing Date Title
DE10346913A DE10346913A1 (de) 2003-10-09 2003-10-09 Acylhydrazonderivate
MXPA06003789A MXPA06003789A (es) 2003-10-09 2004-09-16 Derivados de acilhidrazona.
KR1020067006033A KR20070029106A (ko) 2003-10-09 2004-09-16 아실하이드라존 유도체 및 키나제 신호 변환의 저해, 조절및/또는 조정에서의 이의 용도
CNA2004800295750A CN1863764A (zh) 2003-10-09 2004-09-16 酰基腙衍生物及其在抑制、调节和/或调制激酶信号转导中的用途
EP04765298A EP1670751A1 (de) 2003-10-09 2004-09-16 Acylhydrazonderivate und ihre verwendung bei der hemmung, regulierung und/oder modulation des signaltransduktion von kinasen
PCT/EP2004/010398 WO2005037773A1 (de) 2003-10-09 2004-09-16 Acylhydrazonderivate und ihre verwendung bei der hemmung, regulierung und/oder modulation des signaltransduktion von kinasen
US10/574,781 US7405239B2 (en) 2003-10-09 2004-09-16 Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction
BRPI0415119-4A BRPI0415119A (pt) 2003-10-09 2004-09-16 derivados de acilhidrazona e uso dos mesmos relacionado na inibição, regulação e/ou modulação da transdução do sinal da quinase
JP2006529992A JP2007509037A (ja) 2003-10-09 2004-09-16 アシルヒドラゾン誘導体ならびにキナーゼシグナル伝達の阻害、調節および／または調整におけるそれらの使用
CA002542106A CA2542106A1 (en) 2003-10-09 2004-09-16 Acylhydrazone derivatives and their use in the inhibition, regulation and/or modulation of the signal transduction of kinases
RU2006115795/04A RU2006115795A (ru) 2003-10-09 2004-09-16 Производные ацилгидразона и их применение для ингибирования, регуляции и/или модуляции передачи сигналов с помощью киназы
AU2004281906A AU2004281906A1 (en) 2003-10-09 2004-09-16 Acylhydrazone derivatives and their use in the inhibition, regulation and/or modulation of the signal transduction of kinases
ARP040103650A AR046061A1 (es) 2003-10-09 2004-10-08 Derivados de acilhidrazona
ZA200603631A ZA200603631B (en) 2003-10-09 2006-05-08 Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction
US12/100,987 US20080214674A1 (en) 2003-10-09 2008-04-10 Acylhydrazone derivatives and the use thereof in the inhibition, regulation and/or modulation of kinase signal transduction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10346913A DE10346913A1 (de) 2003-10-09 2003-10-09 Acylhydrazonderivate

Publications (1)

Publication Number Publication Date
DE10346913A1 true DE10346913A1 (de) 2005-05-04

Family

ID=34399391

Family Applications (1)

Application Number Title Priority Date Filing Date
DE10346913A Withdrawn DE10346913A1 (de) 2003-10-09 2003-10-09 Acylhydrazonderivate

Country Status (14)

Country Link
US (2) US7405239B2 (de)
EP (1) EP1670751A1 (de)
JP (1) JP2007509037A (de)
KR (1) KR20070029106A (de)
CN (1) CN1863764A (de)
AR (1) AR046061A1 (de)
AU (1) AU2004281906A1 (de)
BR (1) BRPI0415119A (de)
CA (1) CA2542106A1 (de)
DE (1) DE10346913A1 (de)
MX (1) MXPA06003789A (de)
RU (1) RU2006115795A (de)
WO (1) WO2005037773A1 (de)
ZA (1) ZA200603631B (de)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087985A1 (en) * 2006-01-31 2007-08-09 Merck Patent Gmbh Methods for interfering with glucocorticoid induced gastric acid secretion
WO2007121963A1 (en) * 2006-04-25 2007-11-01 Merck Patent Gmbh Methods for interfering with disease related to impaired mast cell activation
EP2004649A2 (de) * 2006-03-24 2008-12-24 The Feinstein Institute for Medical Research Phenolhydrazone als hemmer des makrophagenmigrationshemmfaktors
WO2009103493A1 (de) * 2008-02-18 2009-08-27 Florian Lang Sgk1 als therapeutisches und diagnostisches target für virale erkrankungen
EP2555766A4 (de) * 2010-04-06 2015-06-03 Univ Brigham Young Antimetastasen-verbindungen

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2558810A1 (en) * 2004-03-08 2005-09-15 Florian Lang Methods for altering insulin secretion
KR20070015148A (ko) * 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 혈청 및 글루코코르티코이드 유도가능한 키나아제의조절제의 용도를 포함하는 신경정신학적 장애를 치료하기위한 글루탐산 수용체의 조절 방법
KR20070015149A (ko) * 2004-03-11 2007-02-01 메르크 파텐트 게엠베하 섬유 형성을 방해하는 방법
DE102004030987A1 (de) * 2004-06-26 2006-01-12 Merck Patent Gmbh Ortho-substituierte (3-Hydroxyphenyl)-essigsäure-benzyliden-hydrazide
DE102005015255A1 (de) * 2005-04-04 2006-10-05 Merck Patent Gmbh Acylhydrazide
DE102005035741A1 (de) * 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
WO2007067812A2 (en) * 2005-12-09 2007-06-14 Metaproteomics, Llc Protein kinase modulation by hops and acacia products
DE102006006648A1 (de) 2006-02-14 2007-08-23 Merck Patent Gmbh Mandelsäurehydrazide
PT2035369E (pt) 2006-07-05 2014-09-30 Fibrotech Therapeutics Pty Ltd Compostos terapêuticos
US8283351B2 (en) * 2007-04-02 2012-10-09 Institute For Oneworld Health Cyclic and acyclic hydrazine derivatives compositions including them and uses thereof
CA2709937C (en) * 2007-12-21 2016-03-22 Fibrotech Therapeutics Pty Ltd Halogenated analogues of anti-fibrotic agents
DE102008010361A1 (de) * 2008-02-18 2009-08-20 Merck Patent Gmbh sgk1-Inhibitoren zur Prophylaxe und/oder Therapie von viralen Erkrankungen und/oder Karzinomen
DE102008029072A1 (de) * 2008-06-10 2009-12-17 Lang, Florian, Prof. Dr.med. Sgk3 als therapeutisches und diagnostisches Target für Alterserkrankungen
JP5665740B2 (ja) * 2008-07-23 2015-02-04 プレジデント アンド フェローズ オブ ハーバード カレッジ デアセチラーゼ阻害剤およびその使用
CA2733378C (en) * 2008-08-05 2017-04-25 Omeros Corporation Pde10 inhibitors and related compositions and methods
DE102008059133A1 (de) * 2008-11-26 2010-05-27 Merck Patent Gmbh Difluorphenyl-diacylhydrazid-derivate
CN101402587B (zh) * 2008-11-28 2012-04-11 中国人民解放军军事医学科学院毒物药物研究所 取代乙酰肼类衍生物及其制备方法和用途
EP2445336A2 (de) 2009-06-23 2012-05-02 Biolex Therapeutics, Inc. Verfahren und zusammensetzungen für die kryokonservierung von wasserlinsen
IN2012DN03312A (de) 2009-10-22 2015-10-23 Fibrotech Therapeutics Pty Ltd
US20140120111A1 (en) 2011-05-19 2014-05-01 The Johns Hopkins University Treatment of autoimmune disorders and infections using antagonists of sgk1 activity
CN103044284A (zh) * 2011-10-13 2013-04-17 南京大学 香草酸酰腙类衍生物及其制备和用途
WO2014011713A2 (en) 2012-07-10 2014-01-16 Dana-Farber Cancer Institue, Inc. Anti-proliferative compounds and uses thereof
CN103880707B (zh) * 2012-12-19 2016-04-13 上海交通大学医学院 Stat3小分子抑制剂及其应用
WO2015171995A1 (en) * 2014-05-08 2015-11-12 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of hiv-1 entry and methods of use thereof
CN105218399B (zh) 2014-05-30 2018-02-09 中国人民解放军军事医学科学院毒物药物研究所 一种取代乙酰肼类衍生物、其制备方法及用途
US11014873B2 (en) 2017-02-03 2021-05-25 Certa Therapeutics Pty Ltd. Anti-fibrotic compounds
KR101839391B1 (ko) * 2018-01-30 2018-03-16 한국생명공학연구원 아실하이드라존 유도체를 포함하는 항염증 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2615188B1 (fr) * 1987-05-14 1989-11-17 Meram Laboratoires Sa Derives d'hydrazine, procede d'obtention et compositions pharmaceutiques les contenant
US6005009A (en) * 1997-03-19 1999-12-21 Duke University Method of inhibiting fibrosis with pyridoxal benzoyl hydrazone and analogs thereof
EP0889127A1 (de) 1997-07-01 1999-01-07 Smithkline Beecham Corporation Serine/Threonine Protein Kinase (H-SGK2)
JPH11106371A (ja) * 1997-07-04 1999-04-20 Nisshin Flour Milling Co Ltd アシルヒドラゾン誘導体
DE19917990A1 (de) 1999-04-20 2000-11-02 Florian Lang Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
EP1296688A2 (de) * 2000-03-23 2003-04-02 Influx, Inc. Bakterizide antimikrobielle methoden and zusammensetzungen zur behandlung von gram positiven infektionen enthaltend einen antibiotischen potentiator mit acyl hydrazid, oxy amid or 8-hydroxy quinolin struktur
DE10042137A1 (de) * 2000-08-28 2002-03-14 Florian Lang sgk2 und sgk3 als diagnostische und therapeutische Targets
US20020077365A1 (en) * 2000-09-08 2002-06-20 The University Of Texas System Method for increasing the effectiveness of antiinfective
AU2002252976A1 (en) * 2001-01-22 2002-09-19 Arpida Ag Hydrazones and their therapeutic use
DE10113876A1 (de) 2001-03-21 2002-09-26 Eberhard Karls Uni Medizinisch Quantitative diagnostische Analyse der Hypertonie
DE10149393A1 (de) 2001-09-28 2003-04-24 Florian Lang sgk1 als diagnostisches und therapeutisches target

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007087985A1 (en) * 2006-01-31 2007-08-09 Merck Patent Gmbh Methods for interfering with glucocorticoid induced gastric acid secretion
EP2004649A2 (de) * 2006-03-24 2008-12-24 The Feinstein Institute for Medical Research Phenolhydrazone als hemmer des makrophagenmigrationshemmfaktors
EP2004649A4 (de) * 2006-03-24 2009-07-15 The Feinstein Inst Medical Res Phenolhydrazone als hemmer des makrophagenmigrationshemmfaktors
US8193247B2 (en) 2006-03-24 2012-06-05 The Feinstein Institute For Medical Research Phenolic hydrazone macrophage migration inhibitory factor inhibitors
AU2007231012B2 (en) * 2006-03-24 2013-07-04 The Feinstein Institute For Medical Research Phenolic hydrazone macrophage migration inhibitory factor inhibitors
US8742173B2 (en) 2006-03-24 2014-06-03 The Feinstein Institute For Medical Research Phenolic hydrazone macrophage migration inhibitory factor inhibitors
WO2007121963A1 (en) * 2006-04-25 2007-11-01 Merck Patent Gmbh Methods for interfering with disease related to impaired mast cell activation
WO2009103493A1 (de) * 2008-02-18 2009-08-27 Florian Lang Sgk1 als therapeutisches und diagnostisches target für virale erkrankungen
EP2555766A4 (de) * 2010-04-06 2015-06-03 Univ Brigham Young Antimetastasen-verbindungen

Also Published As

Publication number Publication date
KR20070029106A (ko) 2007-03-13
US20070060646A1 (en) 2007-03-15
US7405239B2 (en) 2008-07-29
AR046061A1 (es) 2005-11-23
CA2542106A1 (en) 2005-04-28
JP2007509037A (ja) 2007-04-12
AU2004281906A1 (en) 2005-04-28
MXPA06003789A (es) 2006-06-14
RU2006115795A (ru) 2007-11-20
ZA200603631B (en) 2007-01-31
BRPI0415119A (pt) 2006-11-28
US20080214674A1 (en) 2008-09-04
EP1670751A1 (de) 2006-06-21
WO2005037773A1 (de) 2005-04-28
CN1863764A (zh) 2006-11-15

Similar Documents

Publication Publication Date Title
DE10346913A1 (de) Acylhydrazonderivate
FR21C1064I1 (fr) Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
MX2007012156A (es) Acilhidrazidas.
EA200801776A1 (ru) Гидразиды миндальной кислоты
NO20070372L (no) Amidoforbindelser og anvendelse derav som farmasoytiske preparater
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
TW200510328A (en) 5-membered heterocycle-based p38 kinase inhibitors
ATE332129T1 (de) Behandlung der akne mit lipoxygenase inhibitoren
DE69833654D1 (de) Biarylalkansäuren in der verwendung als zelladhäsionsinhibitoren
MY143407A (en) Indazole derivatives as inhibitors of hormone sensitive lipase
BRPI0507053A (pt) métodos para reduzir o dano oxidativo em um mamìfero em necessidade deste, em um órgão removido de um mamìfero e uma célula em necessidade deste
EA201101084A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
SE9800836D0 (sv) New Compounds
DE602004020793D1 (de) 5-phenyl-4-methyl-thiazol-2-yl-amin-derivate als inhibitoren von phosphatidylinositol-3-kinase-enzymen (pi3) zur behandlung entzündlicher erkrankungen der luftwege
TW200510416A (en) P38 inhibitors and methods of use thereof
DE60327745D1 (de) Verwendung von adapalen zur behandlung dermatologischer erkrankungen
EA200702392A1 (ru) Пептид, композиция на его основе, стент с его использованием для лечения патологий, связанных воспалительными процессами, и способ изготовления указанного стента
NO20060978L (no) Farmasoytiske blandingr for behandling av prematur ejakulasjon ved pulmonal inhalering
LU92749I2 (fr) Composition comprenant le virus de la diarrhée virale bovine atténué 1(bvdv-1) et le virus de la diarrhée virale bovine atténué 2 (bvdv-2)
JP2004528464A5 (de)
WO2006041841A1 (en) Phenyl derivatives and methods of use
ATE409065T1 (de) Inhibitoren der 17 beta- hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten
NO20042861L (no) N-(3-butyn-1-yl)-N-hydroksyurea
DE60140871D1 (de) Arylmethylamin-derivate zur verwendung als inhibitoren von tryptase
DE60105418D1 (de) Serinprotease-inhibitoren

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee